How to Speed Up Deruxtecan Payload Screening with ELISA?

Overview

Antibody-drug conjugates (ADCs) such as trastuzumab deruxtecan (T‑DXd) integrate a monoclonal antibody with a highly potent Deruxtecan (DXd) payload. Screening and quantifying the DXd payload accurately and efficiently is critical for ADC development. Traditional bioanalytical methods can be time-consuming, and delays in payload assessment often slow down candidate prioritization. ELISA (enzyme-linked immunosorbent assay) offers a high-throughput, sensitive approach for rapid DXd payload screening, enabling researchers to accelerate decision-making in early ADC development.

ELISA accelerates Deruxtecan payload screening

Understanding the Challenges of DXd Payload Screening

DXd is a small-molecule topoisomerase I inhibitor with potent cytotoxicity, typically present at low concentrations in conjugates. This presents several challenges for screening:

Heterogeneity of ADCs: ADC preparations contain a mixture of unconjugated antibody, partially loaded ADC, and free DXd, complicating quantification.
Low payload concentration: Detecting DXd in plasma or assay matrices often requires high assay sensitivity.
Linker instability: Early release of DXd can skew candidate evaluation if not monitored promptly.

These challenges highlight the need for rapid, reliable assays that can distinguish free DXd from conjugated forms while maintaining high throughput.

Designing DXd-Specific ELISA Assays

Payload-specific ELISA is central to fast DXd screening. Key considerations include:

Capture and detection antibodies: Use monoclonal antibodies targeting DXd or the DXd-linker conjugate to ensure specificity.
Assay format selection:
Sandwich ELISA captures the ADC via the antibody portion and detects DXd with anti-payload antibodies.
Competitive ELISA measures free DXd against immobilized conjugates, enabling direct assessment of payload release.
Signal enhancement: Chemiluminescent substrates and high-efficiency enzyme labels improve detection sensitivity, reducing assay time while maintaining accuracy.

Optimized ELISA design ensures precise quantification of DXd in various matrices and supports rapid candidate triage.

High-Throughput Approaches to Accelerate Screening

Speeding up DXd payload screening requires workflow optimization:

Plate miniaturization: Transitioning to 384- or 1536-well plates allows parallel analysis of multiple ADC candidates with reduced sample and reagent volumes.
Automation: Robotic liquid handling systems streamline sample preparation, reagent addition, and washing steps, minimizing manual labor and variability.
Shortened incubation times: Careful optimization of binding and detection steps can reduce total assay time without sacrificing sensitivity.
Batch processing: Running multiple plates simultaneously with standardized controls enhances reproducibility and throughput.

These strategies enable screening dozens of ADC candidates per day, accelerating lead selection.

Integrating ELISA with Orthogonal Methods

While ELISA provides rapid, sensitive measurements, combining it with orthogonal methods such as LC-MS/MS ensures data reliability:

Confirmatory quantification: LC-MS/MS can validate ELISA measurements of free DXd, reducing false positives caused by matrix effects.
DAR assessment: ELISA alone can approximate payload content, but integrating with LC–MS/MS improves accuracy for complex ADC mixtures.
Early identification of unstable candidates: Parallel ELISA and mass spectrometry analyses allow early detection of linkers prone to premature DXd release.

This integrated approach balances speed with analytical rigor, enabling efficient screening pipelines.

Practical Tips for Faster DXd ELISA Screening

Use high-affinity anti-DXd antibodies to minimize cross-reactivity.
Optimize standard curves with payload-conjugated reference materials to ensure accurate quantification.
Implement signal amplification strategies such as chemiluminescence for low-abundance payloads.
Monitor assay precision and reproducibility across batches to avoid re-testing.
Automate data collection and analysis to rapidly interpret results and prioritize candidates.

Applying these tips reduces assay turnaround time while maintaining confidence in payload measurements.

Case Example: Trastuzumab Deruxtecan Screening

In practice, high-throughput ELISA allows researchers to:

Quickly evaluate DXd release under different linker conditions.
Identify ADC candidates with optimal DAR distribution.
Reduce sample consumption and experimental iterations.
Accelerate the transition from candidate selection to preclinical evaluation.

By integrating optimized ELISA assays into early-stage workflows, laboratories can significantly shorten development timelines.

Conclusion

High-throughput, DXd-specific ELISA is a powerful tool to accelerate ADC payload screening. By designing targeted assays, leveraging automation and miniaturization, and integrating with orthogonal validation methods, researchers can rapidly quantify DXd, prioritize lead candidates, and improve decision-making efficiency. Adopting these strategies not only speeds up payload screening but also enhances the overall quality and reproducibility of ADC development efforts.

FAQ

Antibody FAQs

Still have questions?

01Why is ELISA preferred for Deruxtecan (DXd) payload screening over other methods?

ELISA offers high sensitivity, specificity, and scalability. It allows rapid quantification of DXd, differentiating free payload from conjugated ADC, with relatively low sample consumption and straightforward workflows compared to more complex LC–MS/MS methods.

02What are the main challenges in DXd payload screening?

Key challenges include heterogeneous ADC mixtures, low payload concentrations, and linker instability. These factors can complicate accurate quantification and require sensitive, payload-specific assays.

03How can ELISA workflows be accelerated for high-throughput screening?

Through miniaturization to 384- or 1536-well plates, automation of liquid handling, signal amplification strategies, optimized incubation times, and batch processing. These approaches reduce assay time and improve throughput without sacrificing data quality.

04What ELISA formats are suitable for DXd payload detection?

Common formats include:

Sandwich ELISA: Captures ADC via the antibody portion and detects DXd with anti-payload antibodies.
Competitive ELISA: Measures free DXd against immobilized conjugates.
Indirect ELISA: Uses labeled detection antibodies to quantify DXd concentrations.

05How can assay accuracy be ensured when screening DXd payloads?

Use high-affinity anti-DXd antibodies, establish standard curves with conjugated reference materials, monitor intra- and inter-assay variability, and validate results with orthogonal methods like LC–MS/MS to confirm payload quantification.

Reference

Tsao LC, et al.; Effective extracellular payload release and immunomodulatory interactions govern the therapeutic effect of trastuzumab deruxtecan (T-DXd). Nat Commun. 2025, 16(1):3167.

Reagent Solutions

Dxd Antibodies

Target	Cat. No.	Product Name	Host	Application
DXD	CABT-L828M	Mouse Anti-Dxd monoclonal antibody, clone 13	Mouse	ELISA	Inquiry
	CABT-L0103Y	Mouse Anti-DXD&Exatecan monoclonal Antibody, clone N793	Mouse	PK, PD, IA, ELISA	Inquiry
	CABT-L1055X	Anti-DXD monoclonal antibody	Rabbit	ELISA	Inquiry
	CABT-L1056X	Anti-DXD monoclonal antibody	Rabbit	ELISA	Inquiry
	CABT-L1061X	Anti-DXD monoclonal antibody, Biotin	Rabbit	ELISA	Inquiry
	CABT-L1062X	Anti-DXD monoclonal antibody, PE	Rabbit	FC	Inquiry

Dxd ELISA

Target	Cat. No.	Product Name	Size	Species Reactivity	Application	Detection Sample
DXD	DEIA-JY25377	Deruxtecan (Dxd) ADC ELISA Kit			Quantitative	Serum, plasma	Inquiry

Online Inquiry

Name

Phone

Email *

Technology Interest

Type of Organization

Services & Products Interested *

Project Description

Inquiry Basket

Loading ......

Inquiry